ZA200200035B - Ehrlichia canis genes and vaccines. - Google Patents
Ehrlichia canis genes and vaccines. Download PDFInfo
- Publication number
- ZA200200035B ZA200200035B ZA200200035A ZA200200035A ZA200200035B ZA 200200035 B ZA200200035 B ZA 200200035B ZA 200200035 A ZA200200035 A ZA 200200035A ZA 200200035 A ZA200200035 A ZA 200200035A ZA 200200035 B ZA200200035 B ZA 200200035B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- amino acid
- seq
- dna
- vaccine
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 138
- 229960005486 vaccine Drugs 0.000 title claims description 68
- 241000605312 Ehrlichia canis Species 0.000 title description 39
- 229940051998 ehrlichia canis Drugs 0.000 title description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 101
- 108020004414 DNA Proteins 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 41
- 241000282472 Canis lupus familiaris Species 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 17
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 102000007079 Peptide Fragments Human genes 0.000 claims description 11
- 108010033276 Peptide Fragments Proteins 0.000 claims description 11
- 108060000200 adenylate cyclase Proteins 0.000 claims description 11
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 10
- 102000030621 adenylate cyclase Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000701022 Cytomegalovirus Species 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 241001644525 Nastus productus Species 0.000 claims description 3
- 102000002508 Peptide Elongation Factors Human genes 0.000 claims description 3
- 108010068204 Peptide Elongation Factors Proteins 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 229940044627 gamma-interferon Drugs 0.000 claims description 3
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 241000545125 Tetragoneuria canis Species 0.000 claims 16
- 108020004511 Recombinant DNA Proteins 0.000 claims 9
- 238000010255 intramuscular injection Methods 0.000 claims 6
- 239000007927 intramuscular injection Substances 0.000 claims 6
- 238000010254 subcutaneous injection Methods 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- 101710082714 Exotoxin A Proteins 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 238000003306 harvesting Methods 0.000 claims 2
- 230000009851 immunogenic response Effects 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 1
- 102100039065 Interleukin-1 beta Human genes 0.000 claims 1
- 101150071119 cpg-2 gene Proteins 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 17
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 17
- 108090000233 Signal peptidase II Proteins 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 17
- 241000282465 Canis Species 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 208000000292 ehrlichiosis Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 244000052769 pathogen Species 0.000 description 6
- 108010041986 DNA Vaccines Proteins 0.000 description 5
- 229940021995 DNA vaccine Drugs 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010008038 Synthetic Vaccines Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 229940124551 recombinant vaccine Drugs 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
- 206010020429 Human ehrlichiosis Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 2
- 208000035056 Tick-Borne disease Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108700022487 rRNA Genes Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 description 1
- 241000478345 Afer Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241001481696 Rhipicephalus sanguineus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002152 Splenic rupture Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 101150084863 cya gene Proteins 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000027079 suppression of host defenses Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Ehrlichia canis Genes and Vaccines
The invention pertains to the field of veterinary pathogens. More particularly, the present invention pertains to the sequence of specific genes of the bacterial canine pathogen Ehrlichia canis and the application of this technology to the development of a vaccine.
The present invention relates to the sequence of genes from the E. canis bacterium, and the development of a vaccine against this organism.
Ehrlichia canis (E. canis) is a small gram-negative, obligately intracellular bacterium. This bacteria is the agent which causes canine monocytic ehrlichiosis (CME), a tick-borne disease which predominantly affects dogs. The most common carrier of E. canis is the brown dog tick Rhipicephalus sanguineus. The disease was described originally in Algeria in 1935. It was subsequently recognized in the United States in 1962, but is now known throughout much of the world. Canine monocytic ehrlichiosis caused much concern during the Vietnam War, when 160 military dogs died from the E. canis infection. There is no vaccination currently available against E. canis. It is a life threatening disease that continues to be an important health concern for veterinarians and . pet owners alike.
Canine monocytic ehrlichiosis is an infectious blood disease. A reduction in cellular blood elements is the primary characteristic of the disease. FE. canis lives and reproduces in the white blood cells (leukocytes). It eventually affects the entire lymphatic system, and devastates multiple organs. By targeting the white blood cells, these cells die off rapidly. These dead blood cells migrate primarily to the spleen, which enlarges as a "result. The bone marrow recognizes the loss of the white blood cells and works to form new, healthy cells. It sends out the cells prematurely, and these immature cells do not * work properly. Often, these immature cells mimic those in leukemic patients, so the disease is misdiagnosed as leukemia. Canine monocytic ehrlichiosis may predispose dogs to various cancers.
There are three stages of canine monocytic ehrlichiosis. The first, acute stage mimics a mild viral infection. During the acute stage, most, if not all, of the damage is reversible and the animal is likely to recover. This is the stage where treatment is the most effective, stressing the need for early detection. Without treatment, however, the animal will progress into a subclinical (second) stage and/or to the chronic (final) stage. When the animal has reached the chronic stage, the bacterial organism has settled within the bone marrow. Many dogs in this stage suffer massive internal hemorrhage, or develop lethal complications such as sudden stroke, heart attack, renal failure, splenic rupture or liver failure.
E. canis can be cultured in vitro in a mammalian-derived cell line (DHS82).
Continued maintenance of these cells is difficult because the cell culture must be supplemented with primary monocytes (white blood cells found in bone marrow) every two weeks. The cultures are very slow growing, and the culture media is expensive.
Data concerning the genes in the E. canis genome has concentrated primarily on the 165 rRNA gene. Previous work has sequenced this gene, which is a ubiquitous component of the members of the ehrlichia family, as well as the majority of organisms worldwide. The high sequence homology between this gene throughout the living world makes it a poor candidate for vaccine development. It is necessary to find other genes , within this genome if hope for a vaccine against this deadly disease can ever be realized.
Sequencing of the 168 rRNA gene indicates that E. canis is closely related (98.2% homology) to E. chaffeensis, the novel etiologic agent of human ehrlichiosis. Western blots of E. canis are similar when probed with antisera to E. canis, E. chaffeensis and E.
ewingi (another cause of human ehrlichiosis) indicating a close antigenic relationship ) between these three species (Chen et al., 1994). , The indirect fluorescent antibody test (IFA) has been developed for detecting canine monocytic ehrlichiosis. IFA detects the presence of antibodies against the invading organism in a dog’s blood. Unfortunately, this test is not always accurate. Sometimes, dogs will test negative in the acute phase because their immune system is delayed in forming antibodies. Another false negative may occur if there is a low titer in the chronic stage. An additional drawback of this test is the cross-reactivity found. The anti E. canis polyclonal antibody positively reacts with E. chaffeensis, undermining the specificity of the test. An alternative test, the Giesma smear, has been used to locate the actual organism in a dog’s blood. Unfortunately, despite appropriate staining techniques and intensive film examination, the organisms frequently can not be located. The fallibility of these tests makes it essential to provide better diagnostic tools for this disease.
Due to difficulties in the detection of a tick bite, early diagnosis of infection, the suppression of host defenses and the nature of persistent infection of the disease, an effective vaccine against E. canis is urgently needed for dogs.
This invention discloses novel sequence data for E. canis genes. Specifically, a clone has been identified and sequenced. Four proteins termed ProA, ProB, ORF (an open reading frame with unknown function) and a cytochrome oxidase homolog, have been identified within this clone. In addition, a partial gene encoding a lipoprotein signal peptidase homolog has been discovered.
An embodiment of this invention includes the creation of a vaccine with this ) sequence and protein information. The proteins disclosed in this invention are extremely antigenic. Therefore, they have the potential to be extremely useful as a vaccine. The types of vaccine made available by this novel technology include a DNA vaccine, a . recombinant vaccine, and a T cell epitope vaccine.
Fig. 1 shows the three clones identified in the library screen.
E. canis causes a devastating canine disease. Currently, there is no vaccine available to prevent this disease. This invention provides the tools necessary to develop such a vaccine. More specifically, four genes have been identified from a genomic fragment of E. canis, named ProA, ProB, ORF and a cytochrome oxidase homolog. In addition, a partial gene coding for a lipoprotein signal peptidase homolog has been found. :
Any of these proteins can be utilized in an embodiment of this invention to develop a vaccine.
Screening an E. canis library
To identify genes in the E. canis genome, a genomic DNA expression library was constructed. An E. canis strain isolated from dogs with canine ehrlichiosis was grown in the dog cell line DH82 by a technique being known in the art, and incorporated by reference (Dawson et al., 1991; Rikihisa, 1992). The cells were harvested and the chromosomal DNA extracted as described by a technique known in the art (Chang ef al., 1987; Chang ef al., 1989a; Chang ef al., 1989b; Chang er al., 1993a; Chang ef al., 1993b). . To construct the library, 200 pg of DNA was partially digested with Sau3A. DNA fragments from 3 to 8 kb were isolated and ligated to a plasmid, pHG165 (Stewart er al., ’ 1986). The plasmids were transformed into E. coli TB1 (Chang et al., 1987).
The library was screened with polyclonal antibodies against E. canis. Polyclonal antibodies were generated from dogs that had been bitten by a tick harboring E. canis.
The polyclonal antibodies were preabsorbed with the lysate of an E. coli host strain. The . library was plated on petri plates at a density of 1,000 colony forming units. Colonies were transferred to nitrocellulose and each filter was probed with 1 ml of the preabsorbed ! polyclonal antibodies. Positive colonies were identified with a second antibody consisting of an alkaline phosphatase-conjugated goat anti-rabbit IgG (Kirkegaard and Perry
Laboratories, Gaithersburg, MD), followed by color development with a substrate solution containing nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). Positive clones were rescreened three times.
Three clones were isolated from this screening procedure (Figure 1). The longest genomic fragment (pCH4) encodes four complete genes and one partial gene. It completely encodes the proteins ProA, ProB, ORF and a cytochrome oxidase homolog, as well as containing the partial sequence of a lipoprotein signal peptidase homolog. ProA and ProB are located on a single operon. Restriction endonuclease digestion mapping and
DNA sequencing were done by techniques known in the art, and incorporated by reference (Chang et. al., 1987; Chang et. al., 1989a; Chang et. al., 1989b; Chang et. al., 1993a;
Chang et. al., 1993b). Briefly, the DNA sequence was determined by automated DNA sequencing on the ABI PRISM Model 377 DNA system. The complete nucleotide sequences were determined on both strands by primer walking. The thermal cycling of the sequencing reactions utilized the Taq DyeDeoxy"™ Terminator Cycle sequencing kit.
Databases were searched for homologous proteins through the use of the BLAST network service of the National Center for Biotechnology Information (NCBI) (Althchul ez al., 1990; Gish et al., 1993).
Sequence Information
The E. canis genes were sequenced. The cloned fragment contains 5,300 , nucleotides, and codes for four proteins. There is also one partial gene at the carboxy terminus. SEQ. ID. NO. 1 is the entire nucleotide sequence. SEQ. ID. NO. 2 and 3 are the . translation of nucleotides 12 through 533 from SEQ. ID. NO. 1 and code for a cytochrome oxidase homolog. Cytochrome oxidase is important in virulence, and therefore is a strong candidate for use in a vaccine. SEQ. ID. NO. 4 and 5 are the translation of nucleotides 939 through 2,252 from SEQ. ID. NO. 1 and code for ProA. SEQ. ID. NO. 6 and 7 are the translation of nucleotides 2,258 through 3,664 from SEQ. ID. NO. 1 and code for ProB. . Preliminary evidence indicates that ProA and ProB are proteases. SEQ. ID. NO. 8 and 9 are the translation of nucleotides 4,121 through 4,795 from SEQ. ID. NO. 1 and code for
ORF, a protein with unknown function. SEQ. ID. NO. 10 and 11 are the translation of the complementary sequence of nucleotides 4,884 through 5,300 from SEQ. ID. NO. | and code for the partial sequence of a lipoprotein signal peptidase homolog. Lipoprotein signal peptidases are membrane proteins, and by nature may be less desirable for vaccine development. However, this protein is still worth pursuing in the creation of a vaccine.
Overexpression of ProA, ProB., ORF, cytochrome oxidase and the lipoprotein signal peptidase homolog
The E. canis antigens are overexpressed in a T7 promoter plasmid. The pRSET vector allows high level expression in E. coli in the presence of T7 RNA polymerase, which has a strong affinity for the T7 promoter. After subcloning the antigen genes into the pRSET vector, the subclones are transformed into an F’ E. coli IM109 strain. For maximum protein expression, the transformants are cultured to O.D. 600=0.3, exposed to
IPTG (1 mM) for one hour and then transfected with M13/T7 bacteriophages at a multiplicity of infection (MOI) of 5-10 plaque forming units (pfu) per cell. Time course studies indicate that maximum induction is reached two hours after induction.
The pellet is harvested by centrifugation and the cells are resuspended in 6M
Guanidinium (pH 7.8). Cells are ruptured by French press and the total lysate is spun at 6000 rpm to separate cell debris by a technique known in the art, and hereby incorporated by reference (Chang et al., 1993c). Immobilized metal ion affinity chromatography (IMIAC) is used to purify each of the proteins under denaturing conditions as described by the manufacturer (Invitrogen, San Diego, CA). The protein samples are separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized after staining with coomassie blue.
Vaccine Development
Prior to the present invention, no vaccine against E. canis had been developed. E. canis is endemic in dogs and closely related canidae in many parts of the world. Dogs in
North America are also increasingly at risk and the application of the present invention : can potentially save the lives of thousands of dogs each year. An E. canis vaccine that can elicit cell-mediated immunity against this tick-borne disease of dogs is desperately needed.
DNA Vaccine
A DNA vaccine is constructed by subcloning the gene of interest into a eukaryotic plasmid vector. Candidate vectors include, but are not limited to, pcDNA3, pCI, VR1012, and VR1020. This construct is used as a vaccine.
Each of the newly identified genes, ProA, ProB, ORF, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog can be used to create a DNA vaccine (reviewed in Robinson, 1997). In addition, any immunologically active portion of these proteins is a potential candidate for the vaccine. A plasmid containing one of these genes in an expression vector is constructed. The gene must be inserted in the correct orientation in order for the genes to be expressed under the control of eukaryotic promoters. Possible promoters include, but are not limited to, the cytomegalovirus (CMV) immediate early promoter, the human tissue plasminogen activator (t-PA) gene (characterized in Degen et al., 1986), and the promoter/enhancer region of the human elongation factor alpha (EF-1 a) (characterized in Uetsuki ef al., 1989). Orientation is identified by restriction endonuclease digestion and DNA sequencing.
Expression of these gene products is confirmed by indirect immunofluorescent staining of transiently transfected COS cells. The same plasmid without these genes is used as a control. Plasmid DNA is transformed into Escherichia coli DH5a. DNA is purified by cesium chloride gradients and the concentration is determined by a standard protocol being known in the art, and incorporated by reference (Nyika et al., 1998). ‘ Once the vector is purified, the vector containing the DNA can be suspended in phosphate buffer saline solution and directly injected into dogs. Inoculation can be done via the muscle with a needle or intraveneously. Alternatively, a gene gun can be used to transport DNA-coated gold beads into cells by a technique known in the art, and hereby incorporated by reference (Fynan er al., 1993). The rationale behind this type of vaccine is that the inoculated host expresses the plasmid DNA in its cells, and produces a protein . that raises an immune response. Each of the newly identified genes can be used to create a vaccine by this technique.
CpG molecules can be used as an adjuvant in the vaccine. This technique is known in the art, and is hereby incorporated by reference (Klinman et al., 1997).
Adjuvants are materials that help antigens or increase the immune response to an antigen.
The motifs consist of an unmethylated CpG dinucleotide flanked by two 5° purines and two 3” pyrimidines. Oligonucleotides containing CpG motifs have been shown to activate the immune system, thereby boosting an antigen-specific immune response. This effect can be utilized in this invention by mixing the CpG oligonucleotides with the DNA vaccine, or physically linking the CpG motifs to the plasmid DNA.
Recombinant Vaccine
In order to develop a recombinant vaccine, each of the genes is individually subcloned into overexpression vectors, and then purified for vaccine development. ProA,
ProB, ORF, the cytochrome oxidase homolog or the partial lipoprotein signal peptidase homolog is expressed in a plasmid with a strong promoter such as the tac, T5, or T7 promoter. Alternatively, immunologically active fragments of these proteins are used in the development of a vaccine. Each of these genes is subcloned into a plasmid and transformed into an E. coli strain as described above.
The recombinant protein is overexpressed using a vector with a strong promoter.
Vectors for use in this technique include pREST (Invitrogen Inc., CA), pKK233-3 (Pharmacia, CA), and the pET system (Promega, WI), although any vector with a strong promoter can be used. After overexpression, the proteins are purified and mixed with adjuvant. Potential adjuvants include, but are not limited to, aluminum hydroxide, QuilA, or Montamide. The purified protein is used as immunogen to vaccinate dogs by a technique being known in the art, and incorporated by reference (Chang et al., 1993c;
Chang et al., 1995). Briefly, the individual protein is expressed and purified from E. coli.
Then, the dogs are injected intramuscularly or subcutaneously with the purified recombinant vaccine and adjuvant. This injection elicits an immune response.
T Cell Epitope Vaccine
Direct cell cytoxicity mediated by CD8" T lymphocytes (CTL) is the major mechanism of defense against intracellular pathogens. These effector lymphocytes eliminate infected cells by recognizing short peptides associated with MHC class molecules on the cell surface. Exogenous antigens enter the endosomal pathway and are presented to CD4" T cells in association with class II molecules whereas endogenously synthesized antigens are presented to CD8" T cells in association with MHC class I molecules. E. canis is an intracellular pathogen that resides in monocytes and macrophages. The present invention develops novel ways of generating an E. canis- specific CTL response that would eliminate the organism from monocytes or macrophages of infected animals.
A strategy for increasing the protective response of a protein vaccine is to immunize with selective epitopes of the protein. The rationale behind this is that an epitope vaccine contains the most relevant immunogenic peptide components without the irrelevant portions. Therefore, a search is performed for the most highly antigenic portions of the newly identified proteins.
To identify T-cell epitopes from the newly discovered proteins, an initial electronic search for homologous sequences to known T-cell epitopes is performed. In addition, extensive T-cell epitope mapping is carried out. Each of the proteins, ProA, ProB, ORF, the cytochrome oxidase homolog, and the partial lipoprotein signal peptidase homolog, is tested for immunogenic peptide fragments. Mapping of T cell epitopes by a technique known in the art is hereby incorporated by reference (Launois ef al., 1994; Lee and
Horwitz, 1999). Briefly, short, overlapping peptide sequences (9-20 amino acids) are synthesized over the entire length of the protein in question. These short peptide } fragments are tested using healthy dogs which have been immunized with the protein of interest. Peripheral blood mononuclear cells from the dogs are tested for T cell ‘ stimulatory and IFN-y inducing properties. Those fragments which elicit the strongest response are the best candidates for a T-cell epitope vaccine.
Once fragments are identified which will make the best epitopes, a recombinant . adenylate cyclase of Bordetella bronchiseptica is constructed carrying an E. canis CD8' T cell epitope. The adenylate cyclase toxin (CyaA) of Bordetella bronchiseptica causes ’ disease in dogs and elicits an immune response. In addition, CyaA is well suited for intracytoplasmic targeting. Its catalytic domain (AC), corresponding to the N-terminal 400 amino acid residues of the 1,706-residue-long protein, can be delivered to many eukaryotic cells, including cells of the immune system. Also, toxin internalization is independent of receptor-mediated endocytosis, suggesting that the catalytic domain can be delivered directly to the cytosol of target cells through the cytoplasmic membrane. The
Pseudomonas aeruginosa exotoxin A (PE) is another toxin which could be used in this procedure to deliver peptides or proteins into cells, by a technique known in the art, and hereby incorporated by reference (Donnelly et al., 1993).
Foreign peptides (16 residues) have been inserted into various sites of the AC domain of CyaA without altering its stability or catalytic and calmodulin-binding properties. Thus, protein engineering allows the design and delivery of antigens that specifically stimulate CTLs. The induction of specific CD8" T cells can play an important role in canine ehrlichiosis control due to the intracellular persistence of E. canis in monocytes.
The adenylate cyclase (AC) toxin (cya) gene of B. bronchiseptica has been cloned.
A synthetic double-stranded oligonucleotide encoding a 9 to 20 amino acid class I T cell epitope of either ProA, ProB, ORF, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog, is designed according to B. bronchiseptica codon usage. The complementary oligonucleotides are inserted in the hypervariable region of the cloned AC-coding sequence of the cya. This technique is known in the art in other systems, and is incorporated by reference (Sebo er al., 1995; Guermonprez ef al., 1999).
Recombinant plasmids carrying the chimeric cya gene are sequenced to determine : the copy number and orientation of the inserted epitope. A plasmid with a complete copy of the insert that specifies the T-cell epitope (CD8") in the correct orientation is chosen from the sequenced plasmids. The ability of the new chimeric protein to enter eukaryotic cells is necessary to ensure intracellular targeting of the epitopes (Fayolle er al., 1996).
A vaccine can be created in one of two ways. Recombinant chimeric protein can ‘ be purified and used to inoculate dogs. Alternatively, an attenuated B. bronchiseptica strain that carries a T-cell epitope or E. canis gene by in-frame insertion into adenylate cyclase is created by allelic-exchange. Allelic-exchange is a technique known in the art, and is hereby incorporated by reference (Cotter and Miller, 1994).
Finally, protection against E. canis infection in dogs vaccinated with the adenylase cyclase- ProA, ProB, ORF, cytochrome oxidase homolog, or lipoprotein signal peptidase homolog chimeric protein is determined. Wild type and recombinant ACs and CyAs are diluted to working concentrations in PBS and the chimeric protein is injected into dogs either intramuscularly or subcutaneously. Alternatively, the T-cell epitope is inserted into the adenylate cyclase gene of an attenuated B. bronchiseptica strain in frame, and the dogs are given the live bacteria.
Recombinant antigens are promising candidates for human and animal vaccination against various pathogens. However, a serious drawback is the poor immunogenicity of recombinant antigens as compared to native antigens. A major challenge in the development of a new recombinant vaccine is, therefore, to have a new adjuvant system that increases the immunogenicity of antigens. Cytokines are powerful immunoregulatory molecules. Cytokines which could be used as adjuvants in this invention include, but are not limited to, IL-12 (interleukin-12), GM-CSF (granulocyte-macrophage colony stimulating factor), IL-1 (interleukin-1B) and y-IFN (gamma interferon).
These cytokines can have negative side effects including pyrogenic and/or proinflammatory symptoms in the vaccinated host. Therefore, to avoid the side effects of a whole cytokine protein, an alternate approach is to use synthetic peptide fragments with the desired immunostimulatory properties. The nonapeptide sequence VQGEESNDK of
IL-1p protein is endowed with powerful immuno-enhancing properties, and is discussed here to illustrate the use of a cytokine to increase immunogenicity.
This nonapeptide is inserted into the ProA, ProB, ORF, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog protein and its immunogenicity is compared to that of the native protein. Reportedly, the insertion of this sequence into a poorly immunogenic recombinant antigen increases the chance of a strong . protective immune response after vaccination. This peptide could enhance the in vivo immune response against both T-dependent and T-independent antigens. The canine IL- ‘ 1B sequence may mimic many immunomodulatory activities of the entire molecule of IL- 1B while apparently lacking many of its undesirable proinflammatory properties. This strategy is employed to increase the immunogenicity of ProA, ProB, ORF, cytochrome oxidase, the partial lipoprotein signal peptidase homolog and other E. canis antigens.
Plasmid pYFC199 is derived from a pBR322 plasmid by the insertion of a fragment that includes the ProA, ProB, ORF, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase protein from E. canis. This plasmid contains a unique
Hindlll site where in-frame insertions encoding exogenous sequences can be inserted.
Two complementary oligonucleotides,
AGGCTTGTTCAGGGTGAAGAAGAATCCAACGACAAAAGCTT and
AAGCTTTTGTCGTTGGATTCTTCACCCTGAACTTGCCA, that encode the canine IL- 1B 163-171 peptide are annealed, cut with HindIII, and inserted into the pYFC199 Hindlll site. The recombinant plasmid carrying the chimeric IL-1f gene is sequenced to determine the orientation of the inserted epitope.
The efficacy of the recombinant proteins as vaccines is tested in dogs. The purified protein is injected intraperitoneally into dogs. Specific pathogen free (SPF) dogs are divided into five groups: one group is given recombinant adenylate cyclase of
Bordetella bronchiseptica carrying E. canis CD8” T cell epitopes derived from ProA,
ProB, ORF, cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog, one group is given recombinant adenylate cyclase of Bordetella bronchiseptica as a control, one group is given the ProA, ProB, ORF, cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog protein plus a canine IL-1p 163-171 insert, one group is given a T cell epitope derived from ProA, ProB, ORF, cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog alone, and the last group is given PBS as a negative control.
All animals are vaccinated (30-40 pg each) four times. The dogs are challenged ten : days afer the last vaccination with 10” E. canis. At day five postchallenge, approximately 1 mi blood from each dog is collected in an EDTA tube. Whether the vaccinated groups eliminate the organisms as compared to that of the control group is tested by culture and
PCR Two primers derived from the genes cloned can be used to amplify the gene product from the tissues or blood samples from these dogs. The internal primer can also be designed for use as an oligonucleotide probe to hybridize the PCR gene product.
This invention provides a badly needed vaccine against the E. canis bactermum.
The vaccine can be used to protect dogs throughout the world from canine monocytic ehrlichiosis.
Accordingly, it is to be understood that the embodiments of the invention herein described are merely illustrative of the application of the principles of the invention.
Reference herein to details of the illustrated embodiments are not intended to limit the scope of the claims, which themselves recite those features regarded as essential to the invention.
Claims (1)
- What is claimed is:1 1. A recombinant DNA comprising said DNA selected from the group consisting of: 2 a) arecombinant DNA that encodes a protein having an amino acid sequence as 3 shown in SEQ. ID. NO. 3; 4 b) arecombinant DNA that encodes a protein having an amino acid sequence as shown in SEQ. ID. NO. §; 6 ¢) arecombinant DNA that encodes a protein having an amino acid sequence as 7 shown in SEQ. ID. NO. 7; 8 d) arecombinant DNA that encodes a protein having an amino acid sequence as 9 shown in SEQ. ID. NO. 9; e) arecombinant DNA that encodes a protein having an amino acid sequence as 11 shown in SEQ. ID. NO. 11; and 12 f) any portion of said DNA above that encodes a protein that elicits an immune 13 response against E. canis.1 2. The recombinant DNA of claim 1 wherein said DNA encodes at least one 2 immunogenic epitope.1 3. A recombinant protein comprising said protein selected from the group consisting of: 2 a) a protein having an amino acid sequence as shown in SEQ. ID. NO. 3; 3 b) a protein having an amino acid sequence as shown in SEQ. ID. NO. 5; : 4 ¢) a protein having an amino acid sequence as shown in SEQ. ID. NO. 7; } 5 d) a protein having an amino acid sequence as shown in SEQ. ID. NO. 9; 6 €) a protein having an amino acid sequence as shown in SEQ. ID. NO. 11; and7 f) any portion of any of the above proteins that elicits an immune response 8 against E. canis.1 4. The recombinant protein of claim 3 wherein said protein includes at least one 2 immunogenic epitope.1 5. A vaccine wherein said vaccine protects dogs against E. canis infection.1 6. The vaccine of claim 5 comprising: 2 a) a vector capable of expressing a recombinant DNA inserted into said vector 3 such that a recombinant protein is expressed when said vector is provided in an 4 appropriate host; and b) the recombinant DNA inserted into said vector wherein said DNA is selected 6 from the group consisting of:7 i. arecombinant DNA that encodes a protein having an amino acid 8 sequence as shown in SEQ. ID. NO. 3; 9 ii. arecombinant DNA that encodes a protein having an amino acid sequence as shown in SEQ. ID. NO. 5; 11 iii. arecombinant DNA that encodes a protein having an amino acid 12 sequence as shown in SEQ. ID. NO. 7; 13 iv. arecombinant DNA that encodes a protein having an amino acid 14 sequence as shown in SEQ. ID. NO. 9;v. arecombinant DNA that encodes a protein having an amino acid } 16 sequence as shown in SEQ. ID. NO. 11; and 17 vi. any portion of said DNA above that encodes a protein that elicits an 18 immune response against E. canis.1 7. The vaccine of claim 6, wherein said DNA further comprises DNA that encodes CpG } 2 motifs.1 8. The vaccine of claim 6 wherein said DNA further comprises a promoter selected from 2 the group consisting of: 3 a) a cytomegalovirus (CMV) immediate early promoter; 4 b) a human tissue plasminogen activator gene (t-PA); and ¢) a promoter/enhancer region of a human elongation factor alpha (EF-1 a).1 9. The vaccine of claim 6, wherein said vector is selected from the group consisting of: 2 a) pcDNA3; 3 b) pCl; 4 ¢) VRI1012; and 5 d) VRI1020. 1 10. The vaccine of claim 6 wherein said vaccine is administered into said host by a method 2 selected from the group consisting of: 3 a) intramuscular injection; 4 b) intraveneous injection; and 5 ¢) gene gun injection. 1 11. The vaccine of claim 10, wherein said host is a dog. 1 12. The vaccine of claim 5 comprising: 2 a) a recombinant protein that is selected from the group consisting of:3 i. a protein having an amino acid sequence as shown in SEQ. ID. NO. 3;4 ii. a protein having an amino acid sequence as shown in SEQ. ID. NO. 5;iii. a protein having an amino acid sequence as shown in SEQ. ID. NO. 7; 6 iv. a protein having an amino acid sequence as shown in SEQ. ID. NO. 9;7 v. a protein having an amino acid sequence as shown in SEQ. ID. NO. 11; 8 and 9 vi. any portion of any of the above proteins that elicits an immune response against E. canis. 1 13. The vaccine of claim 12, wherein said vaccine further comprises adjuvants selected 2 from the group consisting of: 3 a) aluminum hydroxide; 4 b) QuilA; and 5 ¢) Montamide. 1 14. The vaccine of claim 12 further comprising a cytokine operatively associated with said 2 recombinant protein. 1 15. The vaccine of claim 14 wherein said cytokine is selected from the group consisting 2 of: 3 a) interleukin-1§ (IL-1PB); 4 b) granulocyte-macrophage colony stimulating factor (GM-CSF); 5 ¢) gamma interferon (y-IFN): 6 d) amino acids VQGEESNDK from the IL-If protein; and 7 e) any portion of any of the cytokines above that elicits an improved 8 immunogenic response against E. canis.1 16. The vaccine of claim 12 wherein said vaccine is administered into a host by a method . 2 selected from the group consisting of: 3 a) intramuscular injection; and 4 b) subcutaneous injection. 1 17. The vaccine of claim 16 wherein said host is a dog. 1 18. The vaccine of claim 5 comprising a recombinant protein that includes a T cell epitope 2 wherein said T cell epitope comprises an amino acid peptide fragment of a protein 3 selected from the group consisting of: 4 a) a protein having an amino acid sequence as shown in SEQ.ID.NO. 3; b) a protein having an amino acid sequence as shown in SEQ.ID.NO. 5; 6 c) a protein having an amino acid sequence as shown in SEQ.ID.NO. 7; 7 d) a protein having an amino acid sequence as shown in SEQ.ID.NO. 9; 8 e) a protein having an amino acid sequence as shown in SEQ.ID.NO. 11; and 9 f) any portion of any of the above proteins that elicits an immune response against E. canis. 1 19. The vaccine of claim 18 wherein said amino acid peptide fragment comprises nine to 2 twenty amino acids. 1 20. The vaccine of claim 18 further comprising a recombinant DNA encoding a protein 2 which is capable of being internalized into eukaryotic cells, including cells of the . 3 immune system. ] 1 21. The vaccine of claim 20 wherein said protein capable of being internalized into 2 eukaryotic cells comprises a toxin selected from the group consisting of: 3 a) a recombinant adenylate cyclase of Bordetella bronchiseptica; and4 b) arecombinant exotoxin A (PE) of Pseudomonas aeruginosa. 1 22. The vaccine of claim 18 wherein said vaccine is administered into a host by a method 2 selected from the group consisting of: 3 a) intramuscular injection; and 4 b) subcutaneous injection. 1 23. The vaccine of claim 22 wherein said host is a dog. 1 24. A method of identifying a T cell epitope against E. canis comprising: 2 a) synthesizing overlapping peptide fragments over an entire length of a protein 3 wherein said protein is selected from the group consisting of:4 i. a protein having an amino acid sequence as shown in SEQ. ID. NO. 3;ii. a protein having an amino acid sequence as shown in SEQ. ID. NO. 5; 6 ili. a protein having an amino acid sequence as shown in SEQ. ID. NO. 7; 7 iv. a protein having an amino acid sequence as shown in SEQ. ID. NO. 9;8 v. a protein having an amino acid sequence as shown in SEQ. ID. NO. 11; 9 and vi. any portion of any of the proteins above that elicits an immune response 11 against E. canis; 12 b) testing said peptide fragment to determine if said peptide fragment elicits an 13 immune response in a host animal; and 14 ¢) identifying said peptide fragment as said T cell epitope of E. canis if said fragment elicits an immune response. 1 25. The method of claim 24 wherein said peptide fragment comprises nine to twenty 2 amino acids.1 26. A method of creating a vaccine against E. canis comprising: 2 a) selecting a vector capable of expressing a recombinant DNA inserted into said 3 vector; and 4 b) inserting a recombinant DNA into said vector such that a recombinant protein is expressed when said vector is provided in an appropriate host wherein said 6 DNA is selected from the group consisting of:7 i. arecombinant DNA that encodes a protein having an amino acid 8 sequence as shown in SEQ. ID. NO. 3; 9 ii. arecombinant DNA that encodes a protein having an amino acid sequence as shown in SEQ. ID. NO. 5; 11 ili. arecombinant DNA that encodes a protein having an amino acid 12 sequence as shown in SEQ. ID. NO. 7; 13 iv. arecombinant DNA that encodes a protein having an amino acid 14 sequence as shown in SEQ. ID. NO. 9;v. arecombinant DNA that encodes a protein having an amino acid 16 sequence as shown in SEQ. ID. NO. 11; and 17 vi. any portion of said DNA above that encodes a protein that elicits an 18 immune response against E. canis. 1 27. The method of claim 26, wherein said DNA further comprises DNA that encodes CpG 2 motifs. 1 28. The method of claim 26 wherein said DNA further comprises a promoter selected from 2 the group consisting of: 3 a) a cytomegalovirus (CMV) immediate early promoter; 4 b) a human tissue plasminogen activator gene (t-PA); and¢) a promoter/enhancer region of a human elongation factor alpha (EF-1 a). 1 29. The method of claim 26, wherein said vector is selected from the group consisting of: 2 a) pcDNA3; 3 b) pCl; 4 ¢) VRI1012; and 5 d) VR1020. 1 30. The method of claim 26 wherein said vaccine is injected into said host in a manner 2 selected from the group consisting of: 3 a) intramuscular injection; 4 b) intraveneous injection; and 5 ¢) gene gun injection. 1 31. The method of claim 30, wherein said host is a dog. 1 32. A method of creating a vaccine against E. canis comprising: 2 a) selecting a vector capable of expressing a recombinant protein inserted into 3 said vector; 4 b) insertion of a recombinant DNA into said vector such that said recombinant 5 protein is expressed when said vector is transformed into a bacterial strain 6 wherein said DNA is selected from the group consisting of: ' 7 i. arecombinant DNA that encodes a protein having an amino acid8 sequence as shown in SEQ.ID.NO. 3; 9 ii. arecombinant DNA that encodes a protein having an amino acid sequence as shown in SEQ.ID.NO. 5;11 iii. arecombinant DNA that encodes a protein having an amino acid : 12 sequence as shown in SEQ.ID.NO. 7; ] 13 iv. arecombinant DNA that encodes a protein having an amino acid 14 sequence as shown in SEQ.ID.NO. 9; 15 v. arecombinant DNA that encodes a protein having an amino acid 16 sequence as shown in SEQ.ID.NO. 11; and 17 vi. any portion of said DNA above that encodes a protein that elicits an 18 immune response against E. canis; and 19 ¢) harvesting said recombinant protein from said bacterial strain. 1 33. The method of claim 32, wherein said vaccine further comprises adjuvants selected 2 from the group consisting of: 3 a) aluminum hydroxide; 4 b) QuilA; and ¢) Montamide. 1 34. The method of claim 32, wherein said vaccine further comprises a promoter selected 2 from the group consisting of: 3 a) tac; 4 b) TS; and 5 cy T7. 1 35. The method of claim 32, wherein said bacterial strain is E. coli. 1 36. The method of claim 32, wherein said vector is selected from the group consisting of: 2 a) pREST;3 b) pET; and 4 ¢) pKK233-3. 1 37. The method of claim 32 wherein said vaccine further comprises a cytokine operatively 2 associated with said vaccine. I 38. The method of claim 37 wherein said cytokine is selected from the group consisting 2 of: 3 a) interleukin-1p (IL-1B); 4 b) granulocyte-macrophage colony stimulating factor (GM-CSF); c) gamma interferon (y-IFN); 6 d) amino acids VQGEESNDK from the IL-If protein; and 7 e) any portion of any of the cytokines above that elicits an improved 8 immunogenic response against E. canis. 1 39. The method of claim 32 wherein said vaccine is injected into said host in a manner 2 selected from the group consisting of: 3 a) intramuscular injection; and 4 b) subcutaneous injection. 1 40. The method of claim 39 wherein said host is a dog. 1 41. A method of creating a T cell epitope vaccine comprising: 2 a) selecting a recombinant protein that includes a T cell epitope wherein said T 3 cell epitope comprises an amino acid peptide fragment of a protein selected 4 from the group consisting of:5 i. a protein having an amino acid sequence as shown in SEQ. ID. NO. 3;6 ii. a protein having an amino acid sequence as shown in SEQ. ID. NO. 5; 7 iii. a protein having an amino acid sequence as shown in SEQ. ID. NO. 7, 8 iv. a protein having an amino acid sequence as shown in SEQ. ID. NO. 9;9 v. a protein having an amino acid sequence as shown in SEQ. ID. NO. 11; and 11 vi. any portion of any of the above proteins that elicits an immune response 12 against E. canis; 13 b) identifying said T cell epitope from said protein; 14 ¢) incorporating said T cell epitope into a construct capable of expressing said epitope as a protein; and 16 d) harvesting said protein. 1 42. The method of claim 41 wherein said amino acid peptide fragment comprises nine to 2 twenty amino acids. 1 43. The method of claim 41 wherein said construct capable of expressing said epitope 2 further comprises a recombinant DNA encoding a protein which is capable of being 3 internalized into eukaryotic cells, including cells of the immune system. 1 44. The method of claim 43 wherein said protein capable of being internalized into 2 eukaryotic cells comprises a toxin selected from the group consisting of: 3 a) a recombinant adenylate cyclase of Bordetella bronchiseptica; and 4 b) a recombinant exotoxin A (PE) of Pseudomonas aeruginosa. 1 45. The method of claim 41 wherein said vaccine is injected into said host in a manner 2 selected from the group consisting of: 3 a) intramuscular injection; and
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35832299A | 1999-07-21 | 1999-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200200035B true ZA200200035B (en) | 2003-10-02 |
Family
ID=23409210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200200035A ZA200200035B (en) | 1999-07-21 | 2002-01-02 | Ehrlichia canis genes and vaccines. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1210438A2 (en) |
JP (1) | JP2003505087A (en) |
CN (1) | CN1367832A (en) |
AU (1) | AU772946B2 (en) |
BR (1) | BR0012556A (en) |
CA (1) | CA2375650A1 (en) |
CZ (1) | CZ2002601A3 (en) |
HK (1) | HK1050708A1 (en) |
IL (1) | IL147733A0 (en) |
MX (1) | MXPA02000748A (en) |
WO (1) | WO2001007625A2 (en) |
ZA (1) | ZA200200035B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7335754B2 (en) | 1999-07-21 | 2008-02-26 | Cornell Research Foundation, Inc. | Ehrlichia canis genes and vaccines |
AU2003290675A1 (en) | 2002-11-07 | 2004-06-03 | Abbott Laboratories | Method of loading beneficial agent to a prosthesis by fluid-jet application |
CA2528727A1 (en) * | 2003-06-10 | 2004-12-16 | The University Of Melbourne | Immunomodulating compositions, uses therefor and processes for their production |
JP6161291B2 (en) * | 2009-11-20 | 2017-07-12 | アバクシス, インコーポレイテッド | Peptides, devices and methods for detection of Ehrlich antibodies |
JP6325553B2 (en) | 2012-10-11 | 2018-05-16 | アバクシス, インコーポレイテッド | Peptides, devices, and methods for detection of Ehrlich antibodies |
US9442112B2 (en) | 2014-04-04 | 2016-09-13 | Abaxis, Inc. | Compositions and methods for identifying Ehrlichia species |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025338A (en) * | 1996-10-17 | 2000-02-15 | University Of Florida | Nucleic acid vaccines against rickettsial diseases and methods of use |
US6207169B1 (en) * | 1997-03-21 | 2001-03-27 | Corixa Corporation | Compounds and methods for the diagnosis and treatment of Ehrlichia infection |
WO1998042743A1 (en) * | 1997-03-24 | 1998-10-01 | Merial | Canine ehrlichiosis immunogenic and diagnostic compositions and methods |
DE69841899D1 (en) * | 1997-09-19 | 2010-10-28 | Ohio State Res Found | PROTEINS OF THE OUTER MEMBRANE OF EHRLICHIA CHAFFEENSIS |
-
2000
- 2000-07-20 CN CN00810608A patent/CN1367832A/en active Pending
- 2000-07-20 CA CA002375650A patent/CA2375650A1/en not_active Abandoned
- 2000-07-20 JP JP2001512891A patent/JP2003505087A/en active Pending
- 2000-07-20 CZ CZ2002601A patent/CZ2002601A3/en unknown
- 2000-07-20 IL IL14773300A patent/IL147733A0/en not_active IP Right Cessation
- 2000-07-20 AU AU62257/00A patent/AU772946B2/en not_active Ceased
- 2000-07-20 BR BR0012556-3A patent/BR0012556A/en not_active Application Discontinuation
- 2000-07-20 WO PCT/US2000/019763 patent/WO2001007625A2/en active IP Right Grant
- 2000-07-20 EP EP00948815A patent/EP1210438A2/en not_active Withdrawn
- 2000-07-20 MX MXPA02000748A patent/MXPA02000748A/en active IP Right Grant
-
2002
- 2002-01-02 ZA ZA200200035A patent/ZA200200035B/en unknown
-
2003
- 2003-03-03 HK HK03101577.6A patent/HK1050708A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL147733A0 (en) | 2002-08-14 |
EP1210438A2 (en) | 2002-06-05 |
AU772946B2 (en) | 2004-05-13 |
CA2375650A1 (en) | 2001-02-01 |
MXPA02000748A (en) | 2003-07-14 |
CZ2002601A3 (en) | 2003-04-16 |
WO2001007625A3 (en) | 2001-10-11 |
WO2001007625A2 (en) | 2001-02-01 |
BR0012556A (en) | 2002-07-02 |
JP2003505087A (en) | 2003-02-12 |
AU6225700A (en) | 2001-02-13 |
CN1367832A (en) | 2002-09-04 |
HK1050708A1 (en) | 2003-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7951386B2 (en) | Ehrlichia canis genes and vaccines | |
JP7385045B2 (en) | African swine fever virus chimeric protein, vaccine composition, preparation method and its application | |
US20120009218A1 (en) | Attenuated Gram Negative Bacteria | |
AU772946B2 (en) | Ehrlichia canis genes and vaccines | |
EP2205625B1 (en) | Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon | |
US7157088B2 (en) | Surface protein of Leptospira | |
CA2311759A1 (en) | Recombinant mycoplasma hyopneumoniae vaccine | |
US20040110269A1 (en) | Protection against mycobacterial infections | |
CA2870179C (en) | Vaccines and methods to treat lyme disease in dogs | |
CN107349423B (en) | Meningococcal antigen combination and application thereof | |
EP1090995B1 (en) | Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof | |
CN104508120A (en) | Recombinant mycobacterium encoding heparin-binding hemagglutinin (hbha) fusion protein and uses thereof | |
EP1240328B1 (en) | Antigenic protein lppq of mycoplasma mycoides subsp. mycoides sc., its preparation and use | |
EP0875574A2 (en) | Live attenuated bacteria of the species Actinobacillus pleuropneumoniae | |
US9562079B2 (en) | Vaccines and methods to treat lyme disease in dogs | |
CN110407944B (en) | Cryptosporidium multi-epitope gene fragment cpmcef, fusion protein and application thereof | |
CN117551670A (en) | Construction and application of mycobacterium bovis and epitope gene recombinant attenuated salmonella | |
CN117551207A (en) | Recombinant subunit vaccine, and preparation method and application thereof | |
ZA200408950B (en) | Attenuated gram negative bacteria |